The Dominant Competing Risk Theorem -- Optimizing One Failure Mode Provably Accelerates Another
Fix one way a protein drug breaks, and you mathematically guarantee another weakness gets worse.
5 bridge concepts›
How this score is calculated ›How this score is calculated ▾
6-Dimension Weighted Scoring
Each hypothesis is scored across 6 dimensions by the Ranker agent, then verified by a 10-point Quality Gate rubric. A +0.5 bonus applies for hypotheses crossing 2+ disciplinary boundaries.
Is the connection unexplored in existing literature?
How concrete and detailed is the proposed mechanism?
How far apart are the connected disciplines?
Can this be verified with existing methods and data?
If true, how much would this change our understanding?
Are claims supported by retrievable published evidence?
Composite = weighted average of all 6 dimensions. Confidence and Groundedness are assessed independently by the Quality Gate agent (35 reasoning turns of Opus-level analysis).
RQuality Gate Rubric
0/10 PASS
| Criterion | Result |
|---|---|
| ABC Structure | true |
| Test Protocol | true |
| Counter-Evidence | true |
| Novelty | true |
| Precision | true |
| Groundedness Adequate | true |
| Mechanism | true |
| Confidence | true |
| Falsifiable | true |
| Claim Verification | true |
Claim Verification
Empirical Evidence
How EES is calculated ›How EES is calculated ▾
The Empirical Evidence Score measures independent real-world signals that converge with a hypothesis — not cited by the pipeline, but discovered through separate search.
Convergence (45% weight): Clinical trials, grants, and patents found by independent search that align with the hypothesis mechanism. Strong = direct mechanism match.
Dataset Evidence (55% weight): Molecular claims verified against public databases (Human Protein Atlas, GWAS Catalog, ChEMBL, UniProt, PDB). Confirmed = data matches the claim.
Protein therapeutics — drugs made of carefully folded proteins, like antibodies or enzyme replacements — are notoriously fragile. They can clump together (aggregate), get chewed up by the body's enzymes (proteolysis), unfold in the heat, oxidize like a cut apple turning brown, or trigger an immune attack. Drug developers work hard to engineer proteins that resist whichever of these failure modes seems most dangerous. This hypothesis says that effort, however successful, is mathematically self-defeating in a precise and provable way. The insight comes from 'competing risks' analysis — a statistical framework developed by actuaries and survival analysts to model situations where multiple causes of failure race against each other. Think of it like a game show where five elimination rounds happen simultaneously, and you're knocked out by whichever one catches you first. The math shows something counterintuitive: if you make a protein better at surviving round one (say, you engineer out its tendency to clump), the protein simply *lives longer* — long enough to now fall victim to rounds two through five at higher rates. Surviving the first threat exposes you to the others. The paper formalizes this as a theorem: reducing the dominant failure mode's hazard *necessarily* raises the cumulative probability of at least one other failure mode. It's not a fluke of bad engineering — it's baked into the math. This matters because the entire field of protein drug design currently optimizes one problem at a time. A team might spend months engineering a protein to resist aggregation, then declare success based on aggregation assays alone — not realizing they've just promoted proteolysis to the new leading cause of drug failure. The theorem suggests those results are systematically overoptimistic, and that true stability requires balancing all five failure modes simultaneously rather than fixing the loudest one.
This is an AI-generated summary. Read the full mechanism below for technical detail.
Why This Matters
If confirmed experimentally, this theorem could fundamentally reshape how protein drugs are designed and tested — pushing the field away from single-metric optimization toward multi-objective stability engineering from day one. It could explain why many promising protein therapeutics that look great in early stability assays still underperform in clinical trials, a costly and persistent problem. Computational protein design tools like RFdiffusion and ProteinMPNN could be updated to incorporate competing-risk objective functions, potentially improving therapeutic half-life predictions and reducing the optimization gap the hypothesis predicts. Given that protein drugs represent a multi-hundred-billion-dollar market and that stability failures are among the top reasons candidates wash out in development, the economic case for testing this theorem rigorously is enormous.
Mechanism
Each designed therapeutic protein faces K=5 competing failure modes: aggregation h_agg(t), proteolysis h_prot(t), thermal unfolding h_unfold(t), oxidative degradation h_ox(t), and immunogenicity h_immune(t). The cumulative incidence function CIF_k(t) = integral_0^t h_k(s) * S(s) ds gives the probability that failure mode k is the first to terminate the protein by time t, where S(t) = exp(-integral_0^t sum_j h_j(s) ds) is the overall survival function.
The key result: for any modification M that reduces the hazard of the dominant failure mode k (the mode with the highest CIF_k(t) at the target timepoint), the CIF of at least one non-dominant mode j necessarily INCREASES. This follows from the mathematical structure: when h_{k} decreases, S(t) increases at every timepoint (the protein survives longer), which increases CIF_j(t) = integral h_j(s) S(s) ds for j != k because the integrand S(s) is now larger. The magnitude of the displacement depends on the ratio of h_j to the total hazard.
Supporting Evidence
Key strength: Mathematical proof guarantees single-mode optimization is suboptimal; not an empirical claim but a theorem. Predictions: 1. Proteins redesigned for aggregation resistance only will show measurably increased proteolysis or oxidation CIF
- At least one non-targeted failure mode CIF increases after redesign
- Total half-life improvement is LESS than 80% of what a single-mode model predicts (the "optimization gap"). Groundedness: 9/10. Claims verified: 5, failed: 0.. Application pathway: enabling_technology (Protein therapeutic development)
How to Test
Take N designed miniproteins, optimize ONLY for aggregation resistance (reduce SAP/APD scores). Measure cause-specific failure rates before and after redesign using: SEC-MALS (aggregation), LC-MS/MS (proteolysis + oxidation), DSF (unfolding), ADA ELISA (immunogenicity) at timepoints 0, 1h, 4h, 24h, 72h, 168h in mouse serum.
Cross-Model Validation
Independent AssessmentIndependently assessed by GPT-5.4 Pro and Gemini 3.1 Pro for triangulation. Assessed independently by two external models for triangulation.
Other hypotheses in this cluster
Competing-Risk Cumulative Incidence Functions as a Unified Protein Therapeutic Lifetime Predictor
PASSA survival statistics framework borrowed from actuaries could predict exactly how—and when—engineered protein drugs will break down in the body.
Competing Risks Censoring Correction for Immunogenicity -- Anti-Drug Antibodies as Interval-Censored Competing Risk
CONDITIONALFixing a hidden flaw in drug safety testing: fast-failing proteins mask their immune risks until it's too late.
Nelson-Aalen Cumulative Hazard Decomposition Reveals Hidden Failure Modes in Accelerated Stability Studies
CONDITIONALSplitting protein drug degradation into its hidden failure modes could make shelf-life predictions far more accurate.
Related hypotheses
Gaussian Mixture Model Analysis of Cryo-EM OMV Populations Distinguishes Biogenesis Pathways in P. aeruginosa
PASSAI-powered microscopy could reveal how bacteria decide what to pack into their tiny 'mail packages'.
Abiotic vs Enzymatic PLOOH Regioselectivity as Chemical Fossil of Antioxidant Evolution
PASSThe chaotic chemistry of ancient iron reactions may have driven evolution of the precise enzymes that now control cell death.
Pyocyanin-GPX4-Ferroptosis Bidirectional Axis
PASSBacteria may hack their own iron supply by triggering a specific type of cell death in human lung cells.
Can you test this?
This hypothesis needs real scientists to validate or invalidate it. Both outcomes advance science.